Navigation Links
NeoStem Announces Participation in Multiple January Conferences
Date:1/4/2012

1, represents NeoStem's most clinically advanced therapeutic and  has commenced enrollment in a Phase 2 trial for the preservation of heart function after a heart attack.  Amorcyte expects to begin a Phase 1 clinical trial in 2012 for AMR-001 for the treatment of patients with congestive heart failure. Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with its partner Becton-Dickinson.  NeoStem's pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes to be an endogenous, pluripotent, non-embryonic stem cell that has the potential to change the paradigm of cell therapy as we know it today.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's prospectus supplement filed with the Securities and Exchange Commission on September 30, 2011. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside i
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeoStems CEO Letter to Shareholders
2. Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management
3. NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
4. NeoStem Announces Participation in Multiple October Conferences
5. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
6. NeoStem Announces Closing of Public Offering for $16,500,000 in Gross Proceeds
7. The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research
8. NeoStem to Present at Two Investor Events This Month
9. NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development
10. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
11. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (PRWEB) July 24, 2014 Your ... advances in modeling lithium-ion battery storage capacity. , ... from a theoretical model created at Lawrence ... that predicts how carbon components will perform ... storage emphasizes the urgent need for higher-performance batteries. ...
(Date:7/24/2014)... San Francisco, CA (PRWEB) July 24, 2014 ... Wednesday to be semi-finalists in Livestrong’s Big C Competition. ... Decisive Health are each headed to the semi-final round. ... in Livestrong’s exclusive three-month accelerator program, complete with mentoring ... country. , As part of the angelMD commitment ...
(Date:7/24/2014)... , July 24, 2014 WIRB-Copernicus Group ... regulatory and ethical review services for clinical research, ... Formerly a division of Richmond, VA ... leading biosafety and biosecurity consulting firm in ... addition, WCG,s biosafety division – WCG Biosafety™ – ...
(Date:7/24/2014)... 24, 2014 Draper University, a ... proud to announce that for 6 weeks this ... will converge on the Draper University campus in ... experiential program focused on entrepreneurship, building real-world skills, ... currently running its sixth cohort, continues to refresh ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3
... Space Place , the University of Wisconsin-Madison's astronomy ... Villager Mall, opening Sunday, Aug. 28. Opening week activities continue ... the public. , ,"We had pretty much outgrown our ... Jim Lattis. "Our programming, our attendance has increased steadily every ...
... aside, every biologist knows that men and women truly are ... where those differences come to the fore: around 80 percent ... play behaviors also differ greatly between the sexes - just ... , ,Early in human development, critical brain proteins known as ...
... Technologies, a life sciences nanotechnology company, has received a ... Medical Sciences. , ,The Small Business Innovation Research grant ... crystal based technology to enable faster screening of drugs ... by using liquid crystals to measure topography on a ...
Cached Biology Technology:Space Place opens new astronomy center 2Gender hormones may lend to social disorder therapies 2
(Date:7/24/2014)... on different species of fish, according to a ... Exeter which tested fish anti-predator behaviour. , ... predator model when exposed to additional noise, whereas ... , Lead author Dr Irene Voellmy of Bristol,s ... many aquatic environments have increased substantially during the ...
(Date:7/24/2014)... terroir, meaning the microbial populations found on surfaces in ... the final flavor according to research published ahead of ... . This is the first time investigators have taken ... Many sake makers inoculate with both bacteria and yeast, ... of California, Davis, but he and his colleagues investigated ...
(Date:7/24/2014)... at NJIT this week for an all-day public forum ... Protection Agency (EPA) to dredge toxic sediment from an ... EPA has called the plan, which proposes removing 4.3 ... of the riverbed, one of the largest cleanups in ... and disposed off-site. , "We need to ensure the ...
Breaking Biology News(10 mins):The microbes make the sake brewery 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2
... scientists survey five New York flu seasons , On the ... for Genomic Research (TIGR) have captured influenza evolution in action. ... , the researchers report the first large-scale project to sequence ... the rapidly evolving flu virus in a human population--and a ...
... RNA is enough to clearly distinguish cancerous thyroid tissue ... findings provide more evidence that an emerging set of ... force in the development of cancer and other diseases. ... Proceedings of the National Academy of Sciences. , Scientists ...
... UK have one of the highest rates of resistance to ... a second wave epidemic of resistant virus, a new study ... concerned that the large reductions in deaths and improvements to ... (combination antiretroviral therapy) may be compromised because of this. , ...
Cached Biology News:First big influenza genome study reveals flu evolution 2First big influenza genome study reveals flu evolution 3First big influenza genome study reveals flu evolution 4Role of microRNA identified in thyroid cancer 2Role of microRNA identified in thyroid cancer 3HIV drug resistance increasing in UK and among highest in the world 2
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
Mouse polyclonal antibody raised against a partial recombinant SYT4. NCBI Entrez Gene ID = 6860...
Mouse monoclonal antibody raised against a partial recombinant IL31RA. NCBI Entrez Gene ID = IL31RA...
Biology Products: